Free Helpline
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Compare Tremfya and Skyrizi, two IL-23 inhibitor biologics for psoriasis, psoriatic arthritis, and Crohn's disease. Learn about their efficacy, side effects, dosing, and key differences to help inform your treatment discussions with a doctor.
Confused about whether CBD can get you high? Understand the difference between CBD and THC, their effects on your body, and what to look for in safe, non-intoxicating CBD products.
April 1, 2026
Learn about anticoagulants and antiplatelet drugs, often called blood thinners. Understand how they prevent blood clots, when they're prescribed, their side effects, and essential safety tips for Indian readers.
April 1, 2026
Chronic inflammatory conditions such as plaque psoriasis, psoriatic arthritis, and Crohn's disease can significantly impact a person's quality of life, often causing persistent pain, discomfort, and visible skin lesions. For many years, treatment options were limited, but the advent of biologic therapies has revolutionized the management of these conditions. Biologics are a class of medications derived from living organisms, designed to target specific parts of the immune system responsible for inflammation. Among the newer generation of biologics, Tremfya (guselkumab) and Skyrizi (risankizumab) have emerged as powerful tools in the fight against these debilitating diseases.
Both Tremfya and Skyrizi belong to a specific class of biologics known as interleukin-23 (IL-23) inhibitors. By selectively blocking the IL-23 pathway, these drugs aim to reduce inflammation and alleviate symptoms associated with autoimmune conditions. While they share a similar mechanism of action, there are subtle differences in their approved indications, administration schedules, clinical efficacy profiles, and side effect considerations that healthcare providers and patients must weigh when choosing the most appropriate treatment. This comprehensive guide will delve into a detailed comparison of Tremfya and Skyrizi, providing essential information to help you understand their roles, benefits, and potential drawbacks, empowering you to have informed discussions with your doctor.
Before diving into the specifics of Tremfya and Skyrizi, it's crucial to understand the conditions they are designed to treat. These conditions are chronic, immune-mediated inflammatory diseases.
Plaque psoriasis is the most common form of psoriasis, affecting millions worldwide. It is characterized by thick, red, scaly patches (plaques) on the skin, often accompanied by itching, burning, and pain. These plaques typically appear on the elbows, knees, scalp, and lower back, but can occur anywhere on the body. The condition results from an overactive immune system that accelerates the growth cycle of skin cells, causing them to build up rapidly on the skin's surface.
Psoriatic arthritis is a chronic inflammatory arthritis that affects some people with psoriasis. It can cause joint pain, stiffness, and swelling, potentially leading to joint damage and disability if left untreated. PsA can affect any joint in the body, including the spine and fingertips, and its symptoms can vary widely from mild to severe.
Crohn's disease is a type of inflammatory bowel disease (IBD) that causes chronic inflammation of the digestive tract. It can affect any part of the GI tract from the mouth to the anus, but most commonly affects the small intestine and the beginning of the large intestine. The inflammation can lead to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition.
Both Tremfya and Skyrizi target interleukin-23 (IL-23), a cytokine that plays a critical role in the inflammatory cascade underlying psoriasis, psoriatic arthritis, and Crohn's disease. IL-23 is produced by various immune cells and is essential for the differentiation and maintenance of Th17 cells, which are potent producers of other pro-inflammatory cytokines like IL-17. By inhibiting IL-23, these biologics effectively disrupt a key pathway in the immune system, leading to a reduction in inflammation and clinical symptoms.
Specifically, Tremfya (guselkumab) and Skyrizi (risankizumab) are monoclonal antibodies that bind to the p19 subunit of the IL-23 cytokine. This binding prevents IL-23 from interacting with its receptor on immune cells, thereby blocking its downstream signaling and the subsequent inflammatory response. This targeted approach offers a significant advantage over older, broader immunosuppressants by precisely modulating the immune system, potentially leading to fewer systemic side effects.
Tremfya, developed by Janssen Biotech, was the first biologic to specifically target the IL-23 p19 subunit. It is approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis.
Tremfya is administered as a subcutaneous injection. The typical dosing schedule for both plaque psoriasis and psoriatic arthritis involves two initial doses given 4 weeks apart, followed by a maintenance dose every 8 weeks. It can be administered by a healthcare professional or, after proper training, by the patient themselves using a prefilled syringe or an auto-injector.
Clinical trials for Tremfya, such as VOYAGE 1, VOYAGE 2, NAVIGATE, and DISCOVER, have demonstrated significant efficacy in achieving clear or almost clear skin (PASI 90/100 response) in patients with plaque psoriasis and improving joint symptoms (ACR20/50/70 response) in patients with psoriatic arthritis. Many patients experience substantial improvement within weeks, with sustained responses over long-term treatment.
Common side effects of Tremfya are generally mild and may include:
Like all biologics, Tremfya can increase the risk of serious infections. Patients should be screened for tuberculosis (TB) before starting treatment and monitored for new infections during therapy. Other serious side effects can include:
Patients should avoid live vaccines while on Tremfya.
Skyrizi, developed by AbbVie, is another highly effective IL-23 inhibitor. It is approved for moderate to severe plaque psoriasis, active psoriatic arthritis, and moderate to severe Crohn's disease.
Skyrizi is also administered via subcutaneous injection. For plaque psoriasis and psoriatic arthritis, the typical dosing schedule is an initial dose, followed by a second dose 4 weeks later, and then maintenance doses every 12 weeks. For Crohn's disease, the initial doses are typically given intravenously (IV) in a clinical setting, followed by subcutaneous maintenance injections every 8 weeks.
Skyrizi has shown impressive efficacy in clinical trials for all its approved indications. For plaque psoriasis, trials like ultIMMa-1 and ultIMMa-2 demonstrated superior skin clearance compared to other biologics. For psoriatic arthritis, the KEEPsAKE 1 and 2 trials showed significant improvements in joint symptoms. In Crohn's disease, trials such as ADVANCE, MOTIVATE, and FORTIFY have shown that Skyrizi can induce and maintain clinical remission and endoscopic improvement.
Common side effects of Skyrizi are generally mild and may include:
Similar to Tremfya, Skyrizi can increase the risk of serious infections. Patients must be screened for TB before starting treatment and monitored for signs of infection. Other serious side effects include:
Live vaccines should be avoided during Skyrizi treatment.
While both drugs target the IL-23 pathway, a direct comparison reveals some key distinctions.
Both Tremfya and Skyrizi are highly effective in treating moderate to severe plaque psoriasis and active psoriatic arthritis. Clinical trials have consistently shown high rates of skin clearance (PASI 90/100) and joint symptom improvement (ACR20/50/70) for both. Some indirect comparisons and a few head-to-head trials (like IMMhance for psoriasis) suggest that Skyrizi might offer a slight edge in achieving very high levels of skin clearance (PASI 90/100) in a shorter timeframe for some patients with plaque psoriasis. However, both drugs provide excellent long-term efficacy, and individual patient responses can vary.
The overall safety profiles of Tremfya and Skyrizi are quite similar, given their shared mechanism of action. Both carry a risk of upper respiratory infections, injection site reactions, and a higher risk of serious infections. There are no major distinguishing safety concerns between the two drugs that would make one unequivocally safer than the other. The decision often comes down to individual patient risk factors and tolerability.
The less frequent dosing schedule of Skyrizi for psoriasis and psoriatic arthritis (every 12 weeks) might be a convenience factor for some patients compared to Tremfya's every 8-week schedule. However, for Crohn's, Skyrizi requires initial IV infusions, which may be a consideration.
This is a significant differentiator:
If a patient has co-existing Crohn's disease along with psoriasis or psoriatic arthritis, Skyrizi might be a more suitable option as it can treat both conditions simultaneously.
Both Tremfya and Skyrizi are high-cost specialty medications. The actual cost to a patient depends heavily on their insurance coverage, deductibles, and co-pays. Manufacturers often offer patient assistance programs to help reduce out-of-pocket expenses. It's essential to discuss cost implications and insurance coverage with your healthcare provider and insurance company.
The choice between Tremfya and Skyrizi is a highly individualized decision that should be made in close consultation with your dermatologist, rheumatologist, or gastroenterologist. Key factors to consider include:
If you are experiencing symptoms of plaque psoriasis, psoriatic arthritis, or Crohn's disease, it is crucial to seek medical advice for proper diagnosis and treatment. Early intervention can significantly impact disease progression and long-term outcomes. If you are already on a biologic therapy and experience any of the following, contact your doctor immediately:
Regular follow-ups with your specialist are essential to monitor your condition, assess treatment effectiveness, and manage any potential side effects.
A1: While highly effective, biologics like Tremfya and Skyrizi are often considered for patients with moderate to severe plaque psoriasis or active psoriatic arthritis who have not responded adequately to conventional systemic therapies (e.g., methotrexate, cyclosporine, phototherapy) or who cannot tolerate them. However, in some cases, especially with severe disease, biologics might be considered earlier in the treatment pathway.
A2: Yes, switching between biologics, including IL-23 inhibitors, is a common practice if a patient experiences primary or secondary treatment failure (lack of initial response or loss of response over time) or intolerable side effects. Your doctor will evaluate your specific situation and guide you on the most appropriate next steps, including the timing and method of switching.
A3: Many patients begin to see improvements in their skin and/or joint symptoms within a few weeks of starting treatment with either Tremfya or Skyrizi. Significant improvements, such as PASI 90/100 for psoriasis or ACR20/50/70 for psoriatic arthritis, are often observed within 16-24 weeks of continuous treatment. For Crohn's disease with Skyrizi, induction of remission can occur within a few weeks, with maintenance therapy continuing thereafter.
A4: Generally, there are no specific dietary restrictions imposed by Tremfya or Skyrizi themselves. However, for conditions like Crohn's disease, dietary modifications are often recommended to manage symptoms, regardless of medication. Patients with psoriasis or psoriatic arthritis may also explore dietary changes that could potentially reduce inflammation, but these are complementary and not a substitute for prescribed treatment.
A5: The use of Tremfya and Skyrizi during pregnancy or breastfeeding has not been extensively studied in humans. Animal studies have not shown direct harm, but generally, these medications are used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is crucial to discuss pregnancy planning and breastfeeding with your doctor if you are considering or are currently taking these medications. They will weigh the risks and benefits and may suggest alternative treatments or adjustments to your current regimen.
Tremfya and Skyrizi represent significant advancements in the treatment of chronic inflammatory diseases by precisely targeting the IL-23 pathway. Both are highly effective biologics capable of providing substantial relief from the debilitating symptoms of plaque psoriasis and psoriatic arthritis, with Skyrizi offering an additional indication for Crohn's disease. While they share many similarities in their mechanism of action and safety profiles, differences in approved uses and dosing schedules can influence treatment decisions.
The choice between Tremfya and Skyrizi is a complex one, requiring a thorough evaluation of your specific condition(s), disease severity, treatment history, personal preferences, and other health factors. It underscores the importance of a strong partnership with your healthcare team. Always engage in open and honest discussions with your dermatologist, rheumatologist, or gastroenterologist to determine which biologic therapy is best suited for your unique needs, helping you achieve the best possible outcomes and improve your quality of life.
This article is based on general medical knowledge, clinical trial data, and prescribing information for Tremfya (guselkumab) and Skyrizi (risankizumab) as approved by regulatory bodies such as the FDA and EMA. For the most current and detailed information, always refer to the official prescribing information provided by the manufacturers and consult with a qualified healthcare professional.
Confused about Plan B and abortion pills? Understand the key differences, how they work, and their effectiveness for informed reproductive health decisions.
April 1, 2026